UBS Group
EFTR

UBS Group’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

UBS Group’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-61,667
Closed -$17.9K – 10494
2024
Q2 		$17.9K Buy
+61,667
New +$146K ﹤0.01% 7369
2024
Q1 		– Sell
-364
Closed -$4.25K – 10273
2023
Q4 		$4.25K Sell
364
-31
-8% -$416 ﹤0.01% 7888
2023
Q3 		$5.92K Buy
+395
New +$6.86K ﹤0.01% 7334
2023
Q2 		– Sell
-857
Closed -$7.56K – 9956
2023
Q1 		$7.56K Sell
857
-194
-18% -$2.35K ﹤0.01% 7796
2022
Q4 		$11.3K Buy
1,051
+389
+59% +$4.94K ﹤0.01% 8413
2022
Q3 		$9K Buy
+662
New +$13K ﹤0.01% 8621
2022
Q2 		– Sell
-6
Closed -$1K – 11183
2022
Q1 		$1K Sell
6
-90
-94% -$12K ﹤0.01% 9982
2021
Q4 		$20K Buy
+96
New +$22.3K ﹤0.01% 7860
2021
Q3 		– Sell
-80
Closed -$20K – 10255
2021
Q2 		$20K Buy
+80
New +$19.7K ﹤0.01% 7349

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group's EFTR Position: Q3 2024 in Review

UBS Group sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 61,667 shares — an estimated $17.9K sold.

UBS Group first reported a position in EFTR in Q2 2021 and held it in 9 quarters. The position peaked at $20K in Q4 2021. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

  • UBS Group reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 61,667 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $17.9K.
  • UBS Group first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
  • UBS Group's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $20K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.